Personalised nutrition: status and perspectives

Joost, Hans‐Georg; Gibney, Michael J.; Cashman, Kevin D.; Görman, Ulf; Hesketh, John E.; Mueller, Michael; Ommen, Ben van; Williams, Christine M.; Mathers, John C.

doi:10.1017/s0007114507685195

Cited by 77 publications

(68 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, there is increasing public interest in genetic testing in the health field, in a study investigating attitudes to genetic testing among 2000 individuals, 81 % of respondents believed that knowing their genetic risk could lead to better control of their lives (108) . A number of studies have reported that individuals identified as having a higher disease risk through genetic testing may be more motivated to change dietary habits (109)(110)(111) . Nevertheless a number of concerns towards genetic testing have been reported including cost, privacy, misuse of genetic information and fear that results could influence insurance companies and job opportunities (107,108,110,112) .…”

Section: Mechanism Of Mthfr C677t Polymorphism Riboflavin and Blood mentioning

confidence: 99%

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

et al. 2016

View full text Add to dashboard Cite

Clinical deficiency of the B-vitamin riboflavin (vitamin B 2 ) is largely confined to developing countries; however accumulating evidence indicates that suboptimal riboflavin status is a widespread problem across the developed world. Few international data are available on riboflavin status as measured by the functional biomarker, erythrocyte glutathione reductase activation coefficient, considered to be the gold standard index. One important role of riboflavin in the form of flavin dinucleotide is as a co-factor for the folate-metabolising enzyme methylenetetrahydrofolate reductase (MTHFR). Homozygosity for the common C677T polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide, has been associated with an increased risk of CVD, and more recently with hypertension. This review will explore available studies reporting riboflavin status worldwide, the interaction of riboflavin with the MTHFR C677T polymorphism and the potential role of riboflavin in personalised nutrition. Evidence is accumulating for a novel role of riboflavin as an important modulator of blood pressure (BP) specifically in individuals with the MTHFR 677TT genotype, with results from a number of recent randomised controlled trials demonstrating that riboflavin supplementation can significantly reduce systolic BP by 5-13 mmHg in these genetically at risk adults. Studies are however required to investigate the BP-lowering effect of riboflavin in different populations and in response to doses higher than 1·6 mg/d. Furthermore, work focusing on the translation of this research to health professionals and patients is also required.Riboflavin: Methylenetetrahydrofolate reductase: MTHFR C677T: Blood pressure:Personalised nutrition Riboflavin (vitamin B 2 ) is a water-soluble B-vitamin defined chemically as 7,8-dimethyl-10-1′-D-ribityl isoalloxazine. It acts as a precursor for FMN and FAD (1) . Clinical riboflavin deficiency is not generally considered to be a problem in the developed world but in recent years evidence has shown that sub-optimal status may be more widespread than generally perceived based on studies reporting the functional biomarker, erythrocyte glutathione reductase activation coefficient (EGRac) generally considered as the gold standard index of status. Few international data are however available based on EGRac and reports on riboflavin status are more commonly based solely on dietary intake data. Although riboflavin is required for numerous metabolic reactions its role (in the form of FAD) as a cofactor for the folatemetabolising enzyme, methylenetetrahydrofolate reductase (MTHFR) has recently received particular attention. Homozygosity (MTHFR 677TT genotype) for a common polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide (2) , has been associated with an increased risk of CVD (3) and more recently with hypertension (4) . Emerging evidence from intervention trials supports a novel role for riboflav...

show abstract

Section: Mechanism Of Mthfr C677t Polymorphism Riboflavin and Blood mentioning

confidence: 99%

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Robust and validated data are difficult to obtain, because of the limited availability of biomarkers of health as well as the high cost of human nutrigenomics intervention studies (20) . However, companies argue there are significant benefits of genotype-based personalised nutrition.…”

Section: Development Of Diet and Lifestyle Assessment Testsmentioning

confidence: 99%

Personalised nutrition: ready for practice?

Roos

2012

Proc. Nutr. Soc.

View full text Add to dashboard Cite

The efficacy by which dietary interventions influence risk markers of multi-factorial diseases is mainly determined by taking population-based approaches. However, there exists considerable inter-individual variation in response to dietary interventions, and some interventions may benefit certain individuals or population subgroups more than others. This review evaluates the application of nutrigenomic technologies to further the concept of personalised nutrition, as well as the process to take personalised nutrition to the marketplace. The modulation of an individual's response is influenced by both genetic and environmental factors. Many nutrigenetics studies have attempted to explain variability in responses based on a single or a few genotypes so that a genotype may be used to define personalised dietary advice. It has, however, proven very challenging to define an individual's responsiveness to complex diets based on common genetic variations. In addition, there is a limited understanding of what constitutes an optimal response because we lack key health biomarkers and signatures. In conclusion, advances in nutrigenomics will undoubtedly further the understanding of the complex interplay between genotype, phenotype and environment, which are required to enhance the development of personalised nutrition in the future. At the same time, however, issues relating to consumer acceptance, privacy protection as well as marketing and distribution of personalised products need to be addressed before personalised nutrition can become commercially viable.

show abstract

“…These challenges will include feeding the growing and ageing world population, better and sustainable use of natural resources as well as improving our ability to exploit foods' potential to prevent diseases and maintain health promote wellness. In this respect, personalized or tailored nutrition seem highly promising and challenging strategies (Joost et al, 2007;Qi, 2014;Zeevi et al, 2015). Such endeavors will require bridging manufacturing capabilities and product engineering to meet the specific needs of the consumer.…”

Section: Rationale and Approach For Extending Ivd Modelsmentioning

confidence: 99%

Extending in vitro digestion models to specific human populations: Perspectives, practical tools and bio-relevant information

Shani-Levi

Alvito

Andrés

et al. 2017

Trends in Food Science & Technology

154

View full text Add to dashboard Cite

a b s t r a c tBackground: In vitro digestion models show great promise in facilitating the rationale design of foods. This paper provides a look into the current state of the art and outlines possible future paths for developments of digestion models recreating the diverse physiological conditions of specific groups of the human population. Scope and approach: Based on a collective effort of experts, this paper outlines considerations and parameters needed for development of new in vitro digestion models, e.g. gastric pH, enzymatic activities, gastric emptying rate and more. These and other parameters are detrimental to the adequate development of in vitro models that enable deeper insight into matters of food luminal breakdown as well as nutrient and nutraceutical bioaccessibility. Subsequently, we present an overview of some new and emerging in vitro digestion models mirroring the gastro-intestinal conditions of infants, the elderly and patients of cystic fibrosis or gastric bypass surgery. Key findings and conclusions: This paper calls for synchronization, harmonization and validation of potential developments in in vitro digestion models that would greatly facilitate manufacturing of foods tailored or even personalized, to a certain extent, to various strata of the human population.

show abstract

Personalised nutrition: status and perspectives

Cited by 77 publications

References 37 publications

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

Personalised nutrition: ready for practice?

Extending in vitro digestion models to specific human populations: Perspectives, practical tools and bio-relevant information

Contact Info

Product

Resources

About